Multi-Omic Patient Stratification in Immune-Mediated Disease: From Cluster to Clinical Decision
DOI:
https://doi.org/10.5281/zenodo.22649493Keywords:
Multi-Omic Patient Stratification in Immune-Mediated Disease; Translational medicine; Evidence synthesis; Clinical implementation; Health services researchAbstract
Multi-Omic Patient Stratification in Immune-Mediated Disease is an area of active development in translational medicine, with
evidence that has accumulated unevenly across its component questions. We review the current evidence base for multi-omic
patient stratification in immune-mediated disease, spanning analytical, clinical, implementation, governance, and economic
dimensions, focusing on where practice has converged and where it continues to vary, and set out the practical considerations
relevant to a service considering its adoption. We conclude that selective, context-specific use is best supported by the evidence
currently available, rather than uniform adoption or avoidance.
References
Alvez D, Dumitrescu A, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.3389/fdgth.2026.1763884
Brankovic K, Kowalczyk B, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.2196/48297
Castellani R, Ristic C, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.1007/s00330-025-12031-z
Dumitrescu A, Andric D, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.3389/fdgth.2026.1699005
Eriksdottir B, Brankovic E, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.3389/fdgth.2026.1834800
Farkas I, Ionescu F, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.2196/69678
Grabowski P, Petrescu G, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.7759/cureus.46454
Hendriksen W, Wojcik H, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.1016/j.ssci.2025.107028
Ionescu F, Foscarini I, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.2196/48633
Jankowiak G, Grabowski J, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.1371/journal.pone.0305949
Kowalczyk N, Novotna K, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.1371/journal.pdig.0000514
Lindqvist U, Urbanek L, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.17219/acem/208596
Marchetti D, Doncheva M, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.7759/cureus.104086
Novotna E, Eriksdottir N, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1038/s41746-023-00852-5
Ostrowski L, Lindqvist O, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.1016/j.mayocpiqo.2022.09.004
Petrescu S, Szabo P, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.1177/08404704241291226
Quintero B, Balogh Q, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.1093/medlaw/fwad013
Ristic C, Castellani R, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.2196/89834
Szabo J, Jankowiak S, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.1007/s10916-024-02104-9
Tarasov Q, Quintero T, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.3389/fdgth.2026.1896184
Urbanek Z, Zielinski U, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.3390/diagnostics15162117
Vasquez A, Alvez V, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.4103/jrpp.jrpp_20_65
Wojcik H, Hendriksen W, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.3389/fdgth.2026.1763884
Zielinski O, Ostrowski Z, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.2196/48297
Andric V, Vasquez A, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.1007/s00330-025-12031-z
Balogh E, Emmerich B, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.3389/fdgth.2026.1699005
Chiriac F, Farkas C, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.3389/fdgth.2026.1834800
Doncheva M, Marchetti D, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a validation study". Trials 22(2017): 377-383. DOI: 10.2196/69678
Emmerich T, Tarasov E, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.7759/cureus.46454
Foscarini C, Chiriac F, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.1016/j.ssci.2025.107028
Alvez D, Dumitrescu A, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.2196/48633
Brankovic K, Kowalczyk B, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.1371/journal.pone.0305949
Castellani R, Ristic C, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.1371/journal.pdig.0000514
Dumitrescu A, Andric D, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.17219/acem/208596
Eriksdottir B, Brankovic E, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.7759/cureus.104086
Farkas I, Ionescu F, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1038/s41746-023-00852-5
Grabowski P, Petrescu G, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.1016/j.mayocpiqo.2022.09.004
Hendriksen W, Wojcik H, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.1177/08404704241291226
Ionescu F, Foscarini I, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a scoping review". JAMA 44(2020): 498-506. DOI: 10.1093/medlaw/fwad013
Jankowiak G, Grabowski J, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.2196/89834
Kowalczyk N, Novotna K, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.1007/s10916-024-02104-9
Lindqvist U, Urbanek L, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.3389/fdgth.2026.1896184
Marchetti D, Doncheva M, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.3390/diagnostics15162117
Novotna E, Eriksdottir N, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.4103/jrpp.jrpp_20_65
Ostrowski L, Lindqvist O, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.3389/fdgth.2026.1763884
Petrescu S, Szabo P, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.2196/48297
Quintero B, Balogh Q, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.1007/s00330-025-12031-z
Ristic C, Castellani R, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.3389/fdgth.2026.1699005
Szabo J, Jankowiak S, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.3389/fdgth.2026.1834800
Tarasov Q, Quintero T, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.2196/69678
Urbanek Z, Zielinski U, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.7759/cureus.46454
Vasquez A, Alvez V, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.1016/j.ssci.2025.107028
Wojcik H, Hendriksen W, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.2196/48633
Zielinski O, Ostrowski Z, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.1371/journal.pone.0305949
Andric V, Vasquez A, et al. "Multi-Omic Patient Stratification in Immune-Mediated Disease: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.1371/journal.pdig.0000514
